Jan 9, 2023 7:00 am EST Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia
Dec 28, 2022 8:00 am EST Opus Genetics Announces Acquisition of the Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases
Dec 6, 2022 6:00 am EST Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
Dec 1, 2022 8:00 am EST Opus Genetics Receives FDA Clearance of IND Application for OPGx-001, a Gene Therapy Candidate Intended for the Treatment of Rare Inherited Retinal Disease LCA5
Nov 14, 2022 8:00 am EST Opus Genetics Sponsors Uni-Rare Natural History Study for People with Inherited Retinal Diseases
Nov 7, 2022 4:05 pm EST Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances
Nov 4, 2022 4:30 pm EDT Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update
Nov 2, 2022 8:09 am EDT Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)
Oct 24, 2022 8:56 am EDT Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting